Regional Guides insights.
Market entry and regulatory strategy by geography
Bay Area Biotech: Companies, Startups and the Silicon Valley Ecosystem
The San Francisco Bay Area raised more biotech venture capital than any other US cluster in 2025. Where the region’s companies cluster, the leading biotechs, investors and incubators, AI and biology, recent deals, and how Bay Area biotechs partner with Asia.
Global Biotech Hubs: The World’s Leading Life Science Clusters and How They Connect
The leading biotech hubs in the US, Europe and Asia, with GEN’s 2026 US cluster data, the Golden Triangle, Basel, Medicon Valley, Shanghai, Suzhou, Hong Kong, Singapore, Tokyo and Songdo, emerging challengers, and how the hubs connect through cross-border deals.
China's Biotech Innovation Clusters: A Site-Selection & Partner-Sourcing Map (2026)
Where to base a NewCo and scout assets across China's four biotech clusters — Suzhou BioBAY, Shanghai Zhangjiang, Beijing Zhongguancun and the Greater Bay Area — with incentives, anchor companies, guiding funds and entry routes for Western firms.
China Biotech in 2026: The Cross-Border Dealmaker's Guide
The dealmaker map of China biotech in 2026: a ~$138B out-licensing supercycle (~186 deals, ~a third of global value), why it happened (NMPA/ICH reform, returnee talent, cost/speed), where the assets are (ADC, PD-1/VEGF, GLP-1, cell therapy), how Western buyers access them (in-license, NewCo, partnership), and the BIOSECURE risk layer.
Chinese AI Drug Discovery Startups: The 2026 Guide
China files ~70% of AI drug-discovery patents and drives a third of global out-licensing value. A dealmaker’s guide to the Chinese AI biotech leaders — Insilico, XtalPi, the “Four Little Dragons” — and how to source and structure cross-border deals.
NMPA Approvals Tracker: China Drug Approvals 2026
NMPA approval news, updated October 2026: 38 Class 1 innovative drugs approved in H1 2026 after a record 2025, the notable approvals, and what each signals for cross-border out-licensing.
China Clinical Trials: Cost, Speed & Regulatory Advantages
Run clinical trials in China and save 60% on costs with 2-5x faster enrollment. NMPA IND process, MRCT strategy for FDA acceptance, BIOSECURE Act clarification, and China CRO landscape guide.
NMPA Drug Approval Process: Complete Guide 2026
China's FDA equivalent explained. Complete guide to NMPA drug approval pathways, IND filing, Breakthrough Therapy Designation, Conditional Approval, and NDA timelines for global pharma companies.
Top Chinese Biotech Companies to Watch in 2026
The definitive guide to China's most innovative biotech companies with active out-licensing pipelines. ADC, bispecific, GLP-1, CAR-T leaders and their global deal pipelines — organized by therapeutic area.
The BIOSECURE Act: Impact on Pharma Supply Chains & China Partnerships
How the landmark legislation signed December 2025 reshapes global biopharma manufacturing, CDMO relationships, and cross-border deal strategy.
Japan Pharma Market Entry Guide: Navigating the World's 4th Largest Market
How to enter Japan's ~$64B pharmaceutical market. PMDA pathways, NHI pricing, partnership models, and cultural considerations.
China Biotech Licensing Opportunities 2026: Assets, Rights and Rules
What global pharma licenses from China, how 2026 deals split worldwide vs ex-China (ROW) rights, and the NMPA, HGR and NRDL rules behind the terms.
The Vision Lifesciences brief.
One email per month. New essays and deal-flow notes from the partner team. Unsubscribe anytime.